Evidence map›Paper›PMID 39375221›Full record

Observational studySupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2024

Early taxane exposure and neurotoxicity in breast cancer patients.

Erika Cimbro, Mariele Dessì, Pina Ziranu, Clelia Madeddu, Francesco Atzori, Eleonora Lai, Andrea Pretta, Stefano Mariani, Clelia Donisi, Dario Spanu and 10 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Chemotherapy-induced peripheral neuropathy in breast cancer: a narrative review.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Erika Cimbro *Medical Oncology Unit, University Hospital and University of Cagliari, 09042, Cagliari, Italy. erikacimbro@gmail.com.
Mariele Dessì *Medical Oncology Unit, University Hospital and University of Cagliari, 09042, Cagliari, Italy.
Pina ZiranuMedical Oncology Unit, University Hospital and University of Cagliari, 09042, Cagliari, Italy.
Clelia MadedduMedical Oncology Unit, University Hospital and University of Cagliari, 09042, Cagliari, Italy.
Francesco AtzoriMedical Oncology Unit, University Hospital and University of Cagliari, 09042, Cagliari, Italy.
Eleonora LaiMedical Oncology Unit, University Hospital and University of Cagliari, 09042, Cagliari, Italy.
Andrea PrettaMedical Oncology Unit, University Hospital and University of Cagliari, 09042, Cagliari, Italy.
Stefano MarianiMedical Oncology Unit, University Hospital and University of Cagliari, 09042, Cagliari, Italy.
Clelia DonisiMedical Oncology Unit, University Hospital and University of Cagliari, 09042, Cagliari, Italy.
Dario SpanuMedical Oncology Unit, University Hospital and University of Cagliari, 09042, Cagliari, Italy.
Marta PozzariMedical Oncology Unit, University Hospital and University of Cagliari, 09042, Cagliari, Italy.
Sara MurgiaMedical Oncology Unit, University Hospital and University of Cagliari, 09042, Cagliari, Italy.
Giorgio SabaMedical Oncology Unit, University Hospital and University of Cagliari, 09042, Cagliari, Italy.
Claudia CodipietroMedical Oncology Unit, University Hospital and University of Cagliari, 09042, Cagliari, Italy.
Enrico PalmasMedical Oncology Unit, University Hospital and University of Cagliari, 09042, Cagliari, Italy.
Giorgia SannaMedical Oncology Unit, University Hospital and University of Cagliari, 09042, Cagliari, Italy.
Francesca SemonellaMedical Oncology Unit, University Hospital and University of Cagliari, 09042, Cagliari, Italy.
Salvatore SardoDepartment of Anesthesia, Resuscitation and Pain Therapy, University of Cagliari, 09042, Cagliari, Italy.
Gabriele FincoDepartment of Medical Sciences and Public Health, University of Cagliari, 09042, Cagliari, Italy.
Mario ScartozziMedical Oncology Unit, University Hospital and University of Cagliari, 09042, Cagliari, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionBreast cancer is the most diagnosed tumor and a leading cause of cancer death in women worldwide. Taxanes are the most used chemotherapeutic agents and are strictly connected to neurotoxicity. Taxane-induced neuropathy (TIN) significantly impacts patients' quality of life (QOL). Early identification and management of TIN could improve preventive strategies to preserve patients' QOL during and after breast cancer treatment.

objectiveThis prospective, observational study aimed to evaluate the taxane-induced neuropathy (TIN) in early breast cancer patients treated with weekly paclitaxel at an earlier stage and identify any correlation between TIN and QOL.

methodsData from stage I-III breast cancer patients treated with taxane-based therapy between 2018 and 2022 were collected at the Medical Oncology Unit of the University Hospital of Cagliari. Peripheral neuropathy was evaluated using the NCI-CTCAE scale (National Cancer Institute, Common Terminology Criteria for Adverse Events) at every drug administration. In contrast, QOL was assessed using EORTC QLC-CIPN20 and FACT-Taxane questionnaire at baseline (T0), after 4 weeks (T1) and 12 (T2) weeks of treatment. Statistical analysis was performed to evaluate the correlation between neurotoxicity and QOL.

resultsNeurotoxicity incidence peaked at the third, fourth, and sixth week of treatment, with patients reporting grade 1 and 2 neurotoxicity. Simultaneously with increasing doses of paclitaxel, significant differences in QOL were observed in early treatment cycles relating to TIN presentation. Patients with higher neurotoxicity grades reported lower QOL scores.

conclusionsDespite the absence of effective treatments to prevent paclitaxel-induced neurotoxicity, symptoms are managed through dosage reduction, delay, or treatment interruption. Future research should focus on identifying neuroprotective measures to avoid an irreversible decline in the quality of life for breast cancer survivors.

Indexed as

Breast NeoplasmsNeurotoxicity SyndromesPaclitaxelPeripheral Nervous System DiseasesQuality of LifeAdultAgedAntineoplastic Agents, PhytogenicBridged-Ring CompoundsFemaleHumansMiddle AgedProspective StudiesTaxoidsAntineoplastic Agents, PhytogenicBridged-Ring CompoundsPaclitaxeltaxaneTaxoidsNeurotoxicityQuality of lifeTaxane

Identifiers

PMID39375221
PMCPMC11458724

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.